Johannes Tauscher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johannes Tauscher has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Siegfried Kasper
Medizinische Universität Wien
6 shared publications - Shitij Kapur
Institute of Psychiatry, King's College London, London, UK
3 shared publications Susanne Asenbaum
Department of Clinical Neurology, University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, Austria
3 shared publicationsBernd Küfferle
Department of General Psychiatry, University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, Austria
2 shared publicationsSitra Tauscher-Wisniewski
2 shared publicationsThomas Brücke
2 shared publications
Latest Publications
- Open Access
- 1 June 2002
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 59 (6) , 514-520
Brain Serotonin 5-HT1A Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635
THERE IS CONSIDERABLE evidence for a role of the neurotransmitter serotonin(5-hydroxytryptamine [5-HT]) in the pathophysiologic characteristics of schizophrenia.1-3 Recent interest in 5-HT has been fueled by the fact that novel antipsychotic drugs such as clozapine, olanzapine, quetiapine, risperidone, sertindole, and ziprasidone hydrochloride are potent 5-HT2A receptor antagonists and relatively weaker dopamine D2 antagonists.4 In addition, 5-HT1A and 5-HT2C receptors seem to contribute to the clinical effects of some novel antipsychotic drugs.5
- 1 June 2002
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 59 (6) , 514-520
Open AccessBrain Serotonin 5-HT1A Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635
THERE IS CONSIDERABLE evidence for a role of the neurotransmitter serotonin(5-hydroxytryptamine [5-HT]) in the pathophysiologic characteristics of schizophrenia.1-3 Recent interest in 5-HT has been fueled by the fact that novel antipsychotic drugs such as clozapine, olanzapine, quetiapine, risperidone, sertindole, and ziprasidone hydrochloride are potent 5-HT2A receptor antagonists and relatively weaker dopamine D2 antagonists.4 In addition, 5-HT1A and 5-HT2C receptors seem to contribute to the clinical effects of some novel antipsychotic drugs.5
- 16 May 2002
- Published by Springer Nature in Psychopharmacology
- Vol. 162 (1) , 42-49
Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol
Rationale. Extrapyramidal symptoms (EPS) are common with conventional antipsychotics. Clozapine and other novel antipsychotic substances with lower in vitro affinity for dopamine-2 (D2) receptors have a lower propensity to induce EPS. Objective. We investigated whether striatal D2 receptor occupancy predicted the occurrence of EPS with atypical antipsychotics and the typical neuroleptic haloperidol. Methods. [123I]Iodobenzamide (IBZM) and single photon emission tomography (SPECT) were used to quantify receptor occupancy in 71 patients treated with antipsychotics. EPS were rated according to the Simpson-Angus scale (SAS). EPS were deemed clinically relevant, if the SAS score was ≥5 and/or anticholinergic medication was required. Patients received atypical antipsychotic monotherapy for at least 14 days with amisulpride (n=2), clozapine (n=6), haloperidol (n=10), olanzapine (n=6), quetiapine (n=4), risperidone (n=14), sertindole (n=13), or zotepine (n=16). Results. The striatal D2 receptor occupancy ranged from 2 receptor occupancy (77%) than those without EPS (61%; P=0.002). We found a positive correlation between the percentage of striatal D2 receptor occupancy and the SAS score (r=0.28; P=0.02), despite 18 of these patients receiving anticholinergics, thus lowering their SAS score. Conclusions. Striatal D2 receptor occupancy as measured with [123I]IBZM and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. In vivo imaging of brain receptors with SPECT may provide a useful clinical tool to titrate doses individually and avoid motor side effects in patients treated with novel antipsychotics.
- 16 May 2002
- Published by Springer Nature in Psychopharmacology
- Vol. 162 (1) , 42-49
Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol
Rationale. Extrapyramidal symptoms (EPS) are common with conventional antipsychotics. Clozapine and other novel antipsychotic substances with lower in vitro affinity for dopamine-2 (D2) receptors have a lower propensity to induce EPS. Objective. We investigated whether striatal D2 receptor occupancy predicted the occurrence of EPS with atypical antipsychotics and the typical neuroleptic haloperidol. Methods. [123I]Iodobenzamide (IBZM) and single photon emission tomography (SPECT) were used to quantify receptor occupancy in 71 patients treated with antipsychotics. EPS were rated according to the Simpson-Angus scale (SAS). EPS were deemed clinically relevant, if the SAS score was ≥5 and/or anticholinergic medication was required. Patients received atypical antipsychotic monotherapy for at least 14 days with amisulpride (n=2), clozapine (n=6), haloperidol (n=10), olanzapine (n=6), quetiapine (n=4), risperidone (n=14), sertindole (n=13), or zotepine (n=16). Results. The striatal D2 receptor occupancy ranged from 2 receptor occupancy (77%) than those without EPS (61%; P=0.002). We found a positive correlation between the percentage of striatal D2 receptor occupancy and the SAS score (r=0.28; P=0.02), despite 18 of these patients receiving anticholinergics, thus lowering their SAS score. Conclusions. Striatal D2 receptor occupancy as measured with [123I]IBZM and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. In vivo imaging of brain receptors with SPECT may provide a useful clinical tool to titrate doses individually and avoid motor side effects in patients treated with novel antipsychotics.
- 1 March 2002
- Published by Springer Nature in Molecular Psychiatry
- Vol. 7 (3) , 317-321
Significant dissociation of brain and plasma kinetics with antipsychotics
Molecular Psychiatry publishes work aimed at elucidating biological mechanisms underlying psychiatric disorders and their treatment
- 1 March 2002
- Published by Springer Nature in Molecular Psychiatry
- Vol. 7 (3) , 317-321
Significant dissociation of brain and plasma kinetics with antipsychotics
Molecular Psychiatry publishes work aimed at elucidating biological mechanisms underlying psychiatric disorders and their treatment
- 1 August 2001
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 158 (8) , 1326-1328
Inverse Relationship Between Serotonin 5-HT1A Receptor Binding and Anxiety: A [11C]WAY-100635 PET Investigation in Healthy Volunteers
OBJECTIVE: The authors investigated the relationship between anxiety—a facet of the Revised NEO Personality Inventory dimension of neuroticism—and serotonin 5-HT1A receptor binding potential. METHOD: Positron emission tomography with [11C]WAY-100635 was used to estimate regional 5-HT1A binding potential in 19 healthy volunteers who completed the Revised NEO Personality Inventory. Correlation coefficients were calculated to determine the degree of association between 5-HT1A binding potential and personality inventory measures. RESULTS: There was a significant negative correlation between 5-HT1A binding potential and anxiety in four regions: the dorsolateral prefrontal cortex, anterior cingulate cortex, parietal cortex, and occipital cortex. CONCLUSIONS: The inverse relationship between 5-HT1A receptor binding potential and anxiety is consistent with 1) animal models that have shown higher anxiety in mice lacking 5-HT1A receptors and 2) clinical trial data that have demonstrated antianxiety properties of partial 5-HT1A agonists.
- 1 August 2001
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 158 (8) , 1326-1328
Inverse Relationship Between Serotonin 5-HT1A Receptor Binding and Anxiety: A [11C]WAY-100635 PET Investigation in Healthy Volunteers
OBJECTIVE: The authors investigated the relationship between anxiety—a facet of the Revised NEO Personality Inventory dimension of neuroticism—and serotonin 5-HT1A receptor binding potential. METHOD: Positron emission tomography with [11C]WAY-100635 was used to estimate regional 5-HT1A binding potential in 19 healthy volunteers who completed the Revised NEO Personality Inventory. Correlation coefficients were calculated to determine the degree of association between 5-HT1A binding potential and personality inventory measures. RESULTS: There was a significant negative correlation between 5-HT1A binding potential and anxiety in four regions: the dorsolateral prefrontal cortex, anterior cingulate cortex, parietal cortex, and occipital cortex. CONCLUSIONS: The inverse relationship between 5-HT1A receptor binding potential and anxiety is consistent with 1) animal models that have shown higher anxiety in mice lacking 5-HT1A receptors and 2) clinical trial data that have demonstrated antianxiety properties of partial 5-HT1A agonists.
- 1 January 2000
- Vol. 41 (1) , 36-44
Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.
[123I]beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane (CIT) is a useful ligand for dopamine transporters (DATs) and serotonin transporters (5-HTTs). Previous SPECT studies have shown a state of sustained equilibrium in the striatum on day 2 after injection that allows quantification of striatal DATs using a simple ratio of specific-to-nondisplaceable binding. The aim of this study was to investigate the kinetics of [123I]beta-CIT uptake in the thalamus, hypothalamus, and midbrain, areas known to contain 5-HTTs in high densities. SPECT with a triple-head camera was performed on 16 healthy volunteers (13 women, 3 men; mean age [+/-SD], 32 +/- 11 y) after intravenous bolus injection of 130 +/- 20 MBq (3.5 +/- 0.5 mCi) [123I]beta-CIT. Two individuals were scanned 1, 2, 4, 7, 10, 13, 16, and 24 h after injection, and the remaining 14 were scanned 4, 7, 10, 20, and 24 h after injection. Values from 19 previously examined healthy volunteers (8 women, 11 men; mean age, 52 +/- 20 y) were included in the analysis to study the age dependency of beta-CIT binding in striatal and 5-HTT-rich brain areas in a larger control sample. Peak uptake 4 h after injection, followed by stable uptake until 10 h and a slow decrease until 24 h, was observed in the thalamus-hypothalamus region. Activity in the midbrain-pons region peaked 2 h after injection. Because of a concomitant slow but steady decline of uptake in reference regions starting 4 h after injection, a higher stability of binding ratios for 5-HTT-rich brain areas was observed on day 2, suggesting that a state of transient equilibrium is reached between 20 and 24 h but that conditions are only close to transient equilibrium between 4 and 10 h after injection for 5-HTT-rich brain areas. In addition to an age-related decline of striatal [123I]beta-CIT binding of 6.6% per decade, a significant age-associated decrease of beta-CIT binding of 3-4% per decade was found in 5-HTT-rich brain areas. The decline of beta-CIT binding in these regions may be explained, at least in part, by a loss of monoamine transporters with age but may also be related to age-associated morphologic changes. [123I]beta-CIT appears to be a suitable ligand for imaging serotonin transporters with SPECT. However, careful age matching is warranted for [123I]beta-CIT SPECT studies of 5-HTT changes in patients with neuropsychiatric disorders.
- 1 January 2000
- Vol. 41 (1) , 36-44
Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.
[123I]beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane (CIT) is a useful ligand for dopamine transporters (DATs) and serotonin transporters (5-HTTs). Previous SPECT studies have shown a state of sustained equilibrium in the striatum on day 2 after injection that allows quantification of striatal DATs using a simple ratio of specific-to-nondisplaceable binding. The aim of this study was to investigate the kinetics of [123I]beta-CIT uptake in the thalamus, hypothalamus, and midbrain, areas known to contain 5-HTTs in high densities. SPECT with a triple-head camera was performed on 16 healthy volunteers (13 women, 3 men; mean age [+/-SD], 32 +/- 11 y) after intravenous bolus injection of 130 +/- 20 MBq (3.5 +/- 0.5 mCi) [123I]beta-CIT. Two individuals were scanned 1, 2, 4, 7, 10, 13, 16, and 24 h after injection, and the remaining 14 were scanned 4, 7, 10, 20, and 24 h after injection. Values from 19 previously examined healthy volunteers (8 women, 11 men; mean age, 52 +/- 20 y) were included in the analysis to study the age dependency of beta-CIT binding in striatal and 5-HTT-rich brain areas in a larger control sample. Peak uptake 4 h after injection, followed by stable uptake until 10 h and a slow decrease until 24 h, was observed in the thalamus-hypothalamus region. Activity in the midbrain-pons region peaked 2 h after injection. Because of a concomitant slow but steady decline of uptake in reference regions starting 4 h after injection, a higher stability of binding ratios for 5-HTT-rich brain areas was observed on day 2, suggesting that a state of transient equilibrium is reached between 20 and 24 h but that conditions are only close to transient equilibrium between 4 and 10 h after injection for 5-HTT-rich brain areas. In addition to an age-related decline of striatal [123I]beta-CIT binding of 6.6% per decade, a significant age-associated decrease of beta-CIT binding of 3-4% per decade was found in 5-HTT-rich brain areas. The decline of beta-CIT binding in these regions may be explained, at least in part, by a loss of monoamine transporters with age but may also be related to age-associated morphologic changes. [123I]beta-CIT appears to be a suitable ligand for imaging serotonin transporters with SPECT. However, careful age matching is warranted for [123I]beta-CIT SPECT studies of 5-HTT changes in patients with neuropsychiatric disorders.
- 11 January 1999
- Published by Springer Nature in Psychopharmacology
- Vol. 141 (2) , 175-181
In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol
We investigated the degree of striatal dopamine-2 (D2) receptor occupancy in six schizophrenic patients receiving clinically effective antipsychotic treatment with olanzapine 10-25 mg/day in comparison to patients treated with clozapine 300-600 mg/day (n = 6) or haloperidol 5-20 mg/day (n = 10). 123I Iodobenzamide (IBZM) and single photon emission computerized tomography (SPECT) were used for the visualization of striatal D2 receptors. For the quantification of striatal D2 receptor occupancy, striatal IBZM binding in patients treated with antipsychotics was compared to that in untreated healthy controls (n = 8) reported earlier. Olanzapine led to a mean striatal D2 receptor occupancy rate of 75% (range 63-85). Haloperidol-treated patients showed dose-dependently (Pearson r = 0.64; P < 0.05) a significantly higher (P < 0.05) mean occupancy rate of 84% (range 67-94). During clozapine treatment, the mean D2 receptor occupancy of 33% (range < 20-49) was significantly lower than with olanzapine (P < 0.005). The higher striatal D2 receptor occupancy of haloperidol was correlated with the incidence and severity of extrapyramidal motor side-effects (EPS). No clinical relevant EPS occurred during treatment with olanzapine or clozapine. There was no correlation between the degree of striatal D2 receptor occupancy and clinical improvement.
- 11 January 1999
- Published by Springer Nature in Psychopharmacology
- Vol. 141 (2) , 175-181
In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol
We investigated the degree of striatal dopamine-2 (D2) receptor occupancy in six schizophrenic patients receiving clinically effective antipsychotic treatment with olanzapine 10-25 mg/day in comparison to patients treated with clozapine 300-600 mg/day (n = 6) or haloperidol 5-20 mg/day (n = 10). 123I Iodobenzamide (IBZM) and single photon emission computerized tomography (SPECT) were used for the visualization of striatal D2 receptors. For the quantification of striatal D2 receptor occupancy, striatal IBZM binding in patients treated with antipsychotics was compared to that in untreated healthy controls (n = 8) reported earlier. Olanzapine led to a mean striatal D2 receptor occupancy rate of 75% (range 63-85). Haloperidol-treated patients showed dose-dependently (Pearson r = 0.64; P < 0.05) a significantly higher (P < 0.05) mean occupancy rate of 84% (range 67-94). During clozapine treatment, the mean D2 receptor occupancy of 33% (range < 20-49) was significantly lower than with olanzapine (P < 0.005). The higher striatal D2 receptor occupancy of haloperidol was correlated with the incidence and severity of extrapyramidal motor side-effects (EPS). No clinical relevant EPS occurred during treatment with olanzapine or clozapine. There was no correlation between the degree of striatal D2 receptor occupancy and clinical improvement.
- 1 January 1999
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 9 (1-2) , 177-179
In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment
- 1 January 1999
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 9 (1-2) , 177-179
In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment
- 4 September 1997
- Published by Springer Nature in Psychopharmacology
- Vol. 133 (1) , 102-105
Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine.
- 4 September 1997
- Published by Springer Nature in Psychopharmacology
- Vol. 133 (1) , 102-105
Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine.